x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012362
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human |
| Applications | WB, IP |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human NUFIP1 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | NUFIP1 |
| UniProt No. | Q9UHK0 |
| Gene ID | 26747 |
| Gene Description | NUFIP1 was identified as an RNA-binding protein shuttling between the nucleus and cytoplasm, and it associates with ribosomes in functional synaptoneurosomes. Reports have shown that NUFIP1 can function as a receptor for starvation-induced ribophagy to maintain protein homeostasis. Ribophagy is a selective form of autophagy targeting ribosomes. Lysosomal levels of NUFIP1 were increased upon inhibition of autophagy. Ribophagy was dependent on the ability of ribosome-associated NUFIP1 to interact with LC3B via a conserved LC3-interacting region domain and recruit ribosomes to the autophagosome. Loss of NUFIP1 or its LC3B binding ability inhibited cell survival following starvation. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
